DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Astal Laboratories Ltd (ASTALLTD) share price today?

Astal Laboratories Ltd (ASTALLTD) is trading at ₹81.28 on the BSE, down 0.67% on the day. Source: DocStoX.

What is the PE ratio of Astal Laboratories Ltd?

Astal Laboratories Ltd has a price-to-earnings (PE) ratio of 8.9 in the Healthcare sector.

What is the market capitalisation of Astal Laboratories Ltd?

Astal Laboratories Ltd has a market capitalisation of approximately ₹358 crore.

Astal Laboratories Ltd

ASTALLTD·BSE·Healthcare

₹81.28▼ -0.55 (-0.67%)

Healthcare · Pharmaceuticals & Biotechnology

High-quality returns — 25% on equity

Day₹80.00

₹83.89

52W₹60

₹10349%

Open

₹83.89

High

₹83.89

Low

₹80.00

Prev Close

₹81.83

Volume

6.8K

VWAP

₹81.48

Snapshot

Key fundamentals

Market Cap

₹358 Cr

P/E Ratio

8.95Cheap

P/B Ratio

1.05

EPS

₹9.08

Book Value

₹77.65

ROE

24.80%Strong

ROCE

34.67%Efficient

Dividend Yield

0.00%

Debt / Equity

0.15Low

Face Value

₹10.00

52W High

₹103.20

52W Low

₹60.45

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Buy

Narrow moatHigh uncertainty

Fair value estimate

₹123

▲ 51.6%upside

Trading at ₹81 — 52% below our estimate

BearFair valueBull

₹70₹123₹142

/100

Business quality — Solid

Growth 50Profitability 83Efficiency 100Valuation 96

Plain English

Our view

High-quality returns — 25% on equity
Low debt relative to equity

Strengths

Low debt relative to equity
Strong returns on equity (25%)
Capital is working hard (ROCE 35%)
Reasonably priced at 9× earnings

How we got there

Fair value methods

Residual income

25% ROE fading to 12% over ~10 yrs, on ₹78 book

₹138

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹70

Analyst target

No analyst coverage

—

Blended fair value₹123

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Strong returns on equity (25%)
Capital is working hard (ROCE 35%)
Reasonably priced at 9× earnings

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

8.9Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

24.8%Strong

Above 15% is considered healthy for Indian equities

ROCE

34.7%Efficient

Above 18% means capital is working hard

Debt/Eq

0.15Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹358 Cr

P/B

1.05

EPS

₹9.08

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Attractive

P/E 8.9×

Growth

N/A

No history

Profitability

Excellent

24.8% ROE

Financial health

Rock solid

D/E 0.15

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹5.56L Cr

Trades72

VWAP₹81.48

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

No growth history

Not enough annual history to compute CAGR.

Profile

Pros

Stock is trading at 1.04 times its book value

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Promoter holding is low: 4.53%
Company has high debtors of 229 days.
Promoter holding has decreased over last 3 years: -56.6%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

Promoter

Promoters

4.5%0.00

Public

80.9%+0.16

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

14.6%

Total shareholders

3,274-39 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter4.53%

Public80.88%

Others14.59%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Astal Laboratories Ltd is engaged in Manufacturing and Trading of all kinds of active Pharmaceutical Ingredients (Bulk Drugs).[1]